Abstract 467P
Background
To investigate the application effect of evidence-based concept of cluster management model in oncology nutrition case management.
Methods
Experimental observation was conducted on 60 cases of oncology patients, and the study period was from August 2021 to August 2022. In the process of nutritional case management of the patients, 30 cases were included in the observation group to carry out the evidence-based concept of the cluster management mode; the other 30 patients belonged to the control group and received routine nursing guidance. Observe and compare the nutritional status and nursing satisfaction of the two groups of patients.
Results
Before nursing care, the nutritional status (S-Amy (blood amylase), U-Amy (urine amylase), Alb (serum albumin), etc.) of the patients in the two groups was assessed, and no significant difference existed between the observation group and the control group (P > 0.05); after the implementation of different nursing care measures, the nutritional status of the patients in the two groups was compared again and found to be significantly different, and that the nutritional status of the patients in the observation group was significantly better ( P＜0.05). The results of patients' satisfaction with nursing interventions showed that the observation group (96.7%) was significantly higher than the control group (70.0%), with a significant difference (P < 0.05).
Conclusions
In the nutritional case management of oncology patients, the implementation of the evidence-based concept of cluster management mode can significantly improve the nutritional status of patients, help patients to strengthen their physical fitness, which is beneficial to the control of patients' conditions, and the patients' satisfaction with nursing care is high, which is worthy of promotion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract